How will they benefit? There are certain types and preparations of cannabis, and we've heard from our friend, Mr. Jones, about the benefits of high-CBD cannabis strains. CBD is not impairing; it's not something we would typically expect recreational users to be seeking out. If you've heard about the medical use of cannabis in the treatment of pediatric epilepsy, those are all high-CBD preparations and, in fact, Tilray—my employer—is involved in a clinical trial at SickKids, looking at high-CBD extract products as a treatment for pediatric epilepsy. If we don't maintain a strong and robust medical cannabis program, those products will likely disappear from the recreational program, because they're simply not impairing; they won't get you high, so there will not be a lot of motivation for their production. Protecting products like that, as well as the use of capsules and orally ingested products in order to discourage the smoking of cannabis, I think, is going to be a very important part of what we can expect in the medical system.
You asked a very important question: will patients still be able to access medical cannabis when recreational cannabis comes around? There are certainly some companies that are clearly hedging their bets more on recreational cannabis and that are already advertising or marketing themselves primarily as recreational cannabis companies. But there are those of us who are determined to focus on the medical cannabis patient, putting money and research into medical cannabis. We'll continue to try to meet the needs of patients across Canada as best we can through legalization and into the future.